Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A2a *via* AKT in prostate cancer cells




Figure S1: LNCaP cells transfected with Dox-controlled inducible PTEN expression system were treated with or without Dox (100 ng/mL) for 24 h. Apolive-Glo Multiplex assays (Promega) were used to determine the effect of PTEN expression on cell proliferation (a) and apoptosis (b). Results represented as the mean \pm SD. * P<0.05 versus no Dox treatment.





Figure S2: Restoration of PTEN expression, inhibition of PI3K, or over-expression of Myr-AKT on cPLA₂ α mRNA levels by RT-qPCR. The experimental cells as described for immunoblotting were harvested. Total RNA was extracted followed by reverse transcription-and quantitative real-time PCR as described under Methods. The Relative Expression Software Tool 2009 (Qiagen) was used to calculate relative changes in cPLA₂ α normalized to the housekeeping gene (TBP). Amplification efficiency was determined using a 5-point dilution curve and was within 100% ± 3% for cPLA₂ α and TBP. * P<0.05 versus control.



(b)

(a)

Figure S3: Effect of protease inhibitor MG132 on cPLA₂ α protein levels. PC-3 cells were treated with the indicated dose of MG132 for 24 h. The cells were harvested and subjected to immunoblot analysis. MG132 had little effect on cPLA₂ α (a) but clearly increased p21 and p27(b).




Figure S4: The effect of blocking GSK3 β (the immediate downstream effector of AKT) on cPLA₂ α . To differentiate whether AKT per se or its target proteins impinge on cPLA₂ α , PC-3 cells treated with the indicated dose of GSK3 β inhibitor for 24 h and subjected to immunoblot (a). Total and pcPLA₂ α proteins levels were unchanged despite the successful inhibition of GSK3 β as shown by the dual luciferase activity of TCF/LEF (TOPO-Flash) promoter assay measuring β -catenin activity (b).